International Journal of Breast Cancer / 2017 / Article / Tab 3

Review Article

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

Table 3

Efficacy results of VICTOR trial in the TNBC population.

VariableOverall

Clinical benefit rate (CR + PR + SD ≥ 24 weeks) (%)10/28 (35.7)
[18.6–55.9]
Kaplan-Meier estimate of median duration of clinical benefit (months)11.3
Disease control rate (CR + PR + SD) 15/28 (53.6%)
Kaplan-Meier estimate of median duration of response in disease control (months)7.4
Kaplan-Meier estimate of median PFS (months)4.7

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.